Literature DB >> 15388437

Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

M Simitsopoulou1, C Gil-Lamaignere, N Avramidis, A Maloukou, S Lekkas, E Havlova, L Kourounaki, D Loebenberg, E Roilides.   

Abstract

Invasive infection due to Scedosporium prolificans is characterized by drug resistance and a high rate of mortality. The effects of posaconazole (POS), an investigational antifungal triazole, murine granulocyte-macrophage colony-stimulating factor (GM-CSF), and their combination against S. prolificans were evaluated ex vivo and in a newly developed murine model of disseminated infection due to this organism. When POS was combined with polymorphonuclear leukocytes from untreated or GM-CSF-treated mice (P < 0.01) ex vivo, it had increased activity in terms of the percentage of hyphal damage. Immunocompetent BALB/c mice were infected with 4 x 10(4) conidia of S. prolificans via the lateral tail vein. At 24 h postinfection the mice were treated with GM-CSF (5 microg/kg of body weight/day subcutaneously), POS (50 mg/kg/day by gavage), both agents, or saline only. Half of the brain, lung, liver, and kidney from each animal were cultured; and the other half of each organ was processed for histopathology. The mean survival times were 7.0 +/- 0.3 days for the controls, 7.4 +/- 0.4 days for POS-treated mice, 8.0 +/- 0.3 days for GM-CSF-treated mice (P = 0.08 compared with the results for the controls), and 7.3 +/- 0.3 days for POS-GM-CSF-treated mice. Fungal burdens (determined as the numbers of CFU per gram of tissue) were found in descending orders of magnitude in the kidneys, brains, livers, and lungs. The burdens were significantly reduced in the brains of GM-CSF-treated mice (P < 0.05) and the livers of POS-treated mice (P < 0.05). The numbers of lesions in the organs closely corresponded to the fungal burdens. GM-CSF tended to prolong survival (P = 0.08 compared with the results for the controls). While the combination of POS and GM-CSF showed enhanced activity ex vivo, it did not increase the activities of the two agents against this highly refractory filamentous fungus in mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388437      PMCID: PMC521885          DOI: 10.1128/AAC.48.10.3801-3805.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  47 in total

Review 1.  Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.

Authors:  M A Ghannoum; L B Rice
Journal:  Clin Microbiol Rev       Date:  1999-10       Impact factor: 26.132

Review 2.  Disseminated phaeohyphomycosis: review of an emerging mycosis.

Authors:  Sanjay G Revankar; Jan E Patterson; Deanna A Sutton; Renee Pullen; Michael G Rinaldi
Journal:  Clin Infect Dis       Date:  2002-01-09       Impact factor: 9.079

3.  Disseminated Scedosporium inflatum infection in a patient with acute myeloblastic leukemia.

Authors:  J Marin; M A Sanz; G F Sanz; J Guarro; M L Martínez; M Prieto; E Gueho; J L Menezo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267

4.  In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.

Authors:  Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 6.  Scedosporium inflatum infection in immunocompromised haematological patients.

Authors:  M Tapia; C Richard; J Baro; R Salesa; J Figols; F Zurbano; A Zubizarreta
Journal:  Br J Haematol       Date:  1994-05       Impact factor: 6.998

Review 7.  Adjunctive immune therapy for fungal infections.

Authors:  A Casadevall; L A Pirofski
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

8.  Scedosporium inflatum: clinical spectrum of a newly recognized pathogen.

Authors:  C M Wilson; E J O'Rourke; M R McGinnis; I F Salkin
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

9.  Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Peter G Pappas; Richard J Hamill; Robert A Larsen; Harold W Horowitz; William G Powderly; Newton Hyslop; Carol A Kauffman; John Cleary; Julie E Mangino; Jeannette Lee
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Clinical features of human infection with Scedosporium inflatum.

Authors:  G M Wood; J G McCormack; D B Muir; D H Ellis; M F Ridley; R Pritchard; M Harrison
Journal:  Clin Infect Dis       Date:  1992-05       Impact factor: 9.079

View more
  7 in total

Review 1.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 2.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

3.  Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection.

Authors:  M Mar Rodríguez; F Javier Pastor; Enrique Calvo; Valentina Salas; Deanna A Sutton; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

Review 4.  Host immune response against Scedosporium species.

Authors:  Emmanuel Roilides; Maria Simitsopoulou; Aspasia Katragkou; Thomas J Walsh
Journal:  Med Mycol       Date:  2009-01-31       Impact factor: 4.076

5.  Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

Authors:  M Mar Rodríguez; Enrique Calvo; Marçal Mariné; F Javier Pastor; Joan Fernandez-Ballart; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

Review 6.  Recent Advances in the Treatment of Scedosporiosis and Fusariosis.

Authors:  Matthew W McCarthy; Aspasia Katragkou; Elias Iosifidis; Emmanuel Roilides; Thomas J Walsh
Journal:  J Fungi (Basel)       Date:  2018-06-18

Review 7.  The Host Immune Response to Scedosporium/Lomentospora.

Authors:  Idoia Buldain; Leire Martin-Souto; Aitziber Antoran; Maialen Areitio; Leire Aparicio-Fernandez; Aitor Rementeria; Fernando L Hernando; Andoni Ramirez-Garcia
Journal:  J Fungi (Basel)       Date:  2021-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.